Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis

Genetics in Medicine

Volumn 12, Issue 4 SUPPL., 2010, Pages

  Chandrasekharan, Subhashini ^a   Pitlick, Emily ^a   Heaney, Christopher ^a   Cook Deegan, Robert ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Genetic testing; Hemochromatosis; HFE; Intellectual property; Patents

Indexed keywords

DNA; HFE PROTEIN; HLA A ANTIGEN;

BIOCHEMISTRY; BLOOD EXAMINATION; CASE STUDY; CLINICAL GENETICS; CONSUMER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HUMAN; INTERPERSONAL COMMUNICATION; IRON OVERLOAD; LABORATORY; LICENSING; MARKETING; ORGANIZATION AND MANAGEMENT; PATENT; PHLEBOTOMY; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; REVIEW;

GENES; GENETIC TESTING; HEALTH SERVICES ACCESSIBILITY; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LICENSURE; MEMBRANE PROTEINS; MUTATION; PATENTS AS TOPIC;

EID: 77951470753     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181d7acb0     Document Type: Review

References (52)

1. National Digestive Diseases Information Clearinghouse (NDDIC). Hemochromatosis. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/ hemochromatosis/index.htm. Accessed November 10, 2008.
2. Schmitt B, Aronson M, Fitterman N, Snow V, Weiss K, Owens D. Screening primary care patients for hereditary hemochromatosis with trasnferrin saturation and serum ferritim level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522-536.
3. Olynyk J, Trinder D, Ramm G, Britton R, Bacon B. Hereditary hemocro-matosis in the post-HFE era. Hepatology 2008;48:991-1001.
4. Crawford D, Hickman P. Screening for hemochromatosis. Hepatology 2000; 31:1192-1193.
5. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 143:517-521. (Pubitemid 41377200)
6. Kowdley KV, Tait JF, Robin BL, Motulsky AG. HFE-associated hemochromatosis. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi? book=gene&part=hemochromatosis. Accessed November 10,2008.
7. Moalen S, Weinberg E, Percy M. Hemochromatosis and the enigma of misplaced iron: implications for infectious disease and survival. Biometals 2004;17:135-139.
8. Cardozo C, Alves H, Mascarenhas M, et al. Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? Immunogenetics 2002;53:1002-1008.
9. Whitlock E, Garlitz B, Harris E, Beil T, Smith P. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventative Services Task Force. Ann Intern Med 2006;145:209-223.
10. Merz J, Kriss A, Leonard D, Cho M. Diagnostic testing fails the test. Nature 2002;415:577-579.
11. McDonnell SW, Witte DL, Cogswell M, McIntyre R. Strategies to increase detection of hemochromatosis. Ann Intern Med 1998;129:987-992.
12. Yen A, Fancher T, Bowlus C. Revisiting hereditary hemochromatosis: current concepts and progress. Am J Med 2006;119:391-399.
13. Wood M, Powell L, Ramm G. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008;111: 4456-4462.
14. Franchini M, Veneri D. Hereditary hemochromatosis. Hematology 2005;10: 145-149.
15. Park C, Valore E, Waring A, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
16. Krause A, Neitz S, Mägert H. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-150.
17. ACC Review of HHC/General Adult Population Analytic Validity. Centers for Disease Control; 2003 http://www.cdc.gov/genomics/gtesting/ACCE/FBR/HH/ HHAnaVal-17.htm. Accessed January 12 2009.
18. Adams P, Reboussin D, Press R. Biological variability of transferrin saturation and unsaturated iron binding capacity. Am J Med 2007;120:999.e991.- e997.
19. Adams P, Reboussin D, Eckfeldt J. A comparison of the unsaturated iron binding capacity to transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the HEIRS study. Clin Chem 2005;51:1048-1052.
20. Murtagh L, Whiley M, Wilson S, Tran H, Bassett M. Unsaturated iron binding capacity and transferrin saturation are equally reliable in detection of HFE hemochromatosis. Am J Gastroenterol 2002;97:2093-2099.
21. Adams P, Kertesz A, McLaren C, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Ann Intern Med 2000;31:1160-1164.
22. Powell L, George D, McDonnell S, Kowdley K. Diagnosis of hemochro-matosis. Ann Intern Med 1998;129:925-931.
23. Falize L, Guillygomarch A, Perrin M. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44:472-477. (Pubitemid 44214887)
24. Powell L, Dixon J, Ramm G. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166: 294-301. (Pubitemid 43244317)
25. Anderson R, Wenzel L, Walker A, et al. Impact of hemochromatosis screening in patients with indeterminate results: the hemochromatosis and iron overload screening study. Genet Med 2006;8:681-687. (Pubitemid 44772795)
26. Feder J, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13: 399-408. (Pubitemid 26256612)
27. Nanogen and Bio-Rad sign licensing agreement. Biotech Patent News. June 1, 2002. Available at: http://www.encyclopedia.com/doc/1G1-89013216.html. Accessed March 9, 2010.
28. Cho M. Effects of gene patents and licenses on clinical genetic testing. Bethesda, MD: Secretary's Advisory Committee on Genetics, Health, and Society, 2006. Available at: http://oba.od.nih.gov/oba/SACGHS/meetings/June2006/Cho.pdf. Accessed November 12, 2008.
29. Phatak P, Bonkovsky H, Kowdley K. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008;149:270-272.
30. Adams P, Valberg L. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999;94:1593-1600. (Pubitemid 29260451)
31. Waalen J, Nordestgaard B, Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 2005;18:203-220. (Pubitemid 40298365)
32. El-Serag H, Inadomi J, Kowdley K. Screening for hereditary hemochromatosis in siblings and children of affected patients, a cost-effectiveness analysis. Ann Intern Med 2000;132:261-269. (Pubitemid 30106256)
33. Allen KJ, Gurrin LC, Constantine CC. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-230.
34. Gagne G, Reinharz D, Laflamme N, Adams P, Rousseau F. Hereditary hemochromatosis: effect of mutation penetrance and prevalence on cost-effectiveness of screening modalities. Clin Genet 2007;71:46-58. (Pubitemid 44921621)
35. Gordon R. An operational definition of disease prevention. Public Health Rep 1983;98:107-109.
36. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-251.
37. Jouanolle A, Gandon G, Jezequel P. Hemochromatosis and HLA-H (Letter). Nat Genet 1996;14:251-252.
38. Fackelmann K. Rusty origins: researchers identify the gene for iron-overload disease. Sci News. January 18, 1997. Available at: http://findarticles.com/p/articles/mi-m1200/is-n3-v151/ai-19056180/pg-1?tag= artBody;col1. Accessed January 12, 2009.
39. Associated Press. Gene found for iron buildup. New York Times. July 31, 1996:C-7.
40. Adams P, Reboussin D, Barton J. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-1778 (Pubitemid 40570925)
41. Transcript of a conference call held by Hologic, Inc on June 9, 2008. SEC Accession No. 0001193125-08-130599. San Francisco, CA: SEC, 2008. Available at: http://www.sec.gov/Archives/edgar/data/859737/0001193125 08130599/0001193125- 08-130599-index.htm. Accessed March 3, 2010.
42. Capitalizing on the genome. Nat Genet 1996;13:1-5. Available at: http://www.sec.gov/Archives/edgar/data/859737/000119312508130599/ 0001193125-08-130599-index.htm Accessed March 10, 2010
43. Progenitor files registration statements for initial public offering of 2,750,000 shares and for acquisition of Mercator Genetics Inc. Business Wire. March 14, 1997.
44. American Hemochromatosis Society home page. Available at: http://www.americanhs.org. Accessed May 3, 2007.
45. Hemochromatosis for health care professionals: genetic testing and basic counseling. Available at: http://www.cdc.gov/ncbddd/hemochromatosis/training/ family-detection/testing-and-counseling.htm. Accessed November 12, 2008.
46. Hemochromatosis for health care professionals: diagnostic testing. Available at: http://wwwcdc.gov/ncbddd/hemochromatositesting-protocol.htm Accessed November 12, 2008.
47. Allen A. Policing the gene machine. Lingua Franca 1997;8:29-36. Available at: http://linguafranca.mirror.theinfo.org/9703/Policing6.html. Accessed May 2, 2007.
48. Hall M, Barton J, Adams P, et al. Genetic screening for iron overload: no evidence of discrimination at one year. JFam Pract 2007;56:829-833. (Pubitemid 350072156)
49. Who should consider testing for hemochromatosis? Available at: http://www.dnadirect.com/web/article/testing-for-genetic-disorders/ hemochromatosis/36/who-shouldconsider-testing. Accessed January 12, 2009.
50. Shute N. Unraveling your DNA's secret. US News World Rep 2007;142: 50-54; 57-58.
51. Ramrakhiani S, Bacon B. Hemochromatosis: advances in molecular genetics and clinical diagnosis. J Clin Gastroenterol 1998;27:41-46. (Pubitemid 28357623)
52. Morrison E, Brandhagen D, Phatak P, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003;138:627-633. (Pubitemid 38124653)